KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-Current Deffered Revenue (2016 - 2017)

Historic Non-Current Deffered Revenue for Supernus Pharmaceuticals (SUPN) over the last 7 years, with Q4 2017 value amounting to $1.1 million.

  • Supernus Pharmaceuticals' Non-Current Deffered Revenue fell 2345.1% to $1.1 million in Q4 2017 from the same period last year, while for Dec 2017 it was $1.1 million, marking a year-over-year decrease of 2345.1%. This contributed to the annual value of $1.1 million for FY2017, which is 2345.1% down from last year.
  • Supernus Pharmaceuticals' Non-Current Deffered Revenue amounted to $1.1 million in Q4 2017, which was down 2345.1% from $1.2 million recorded in Q3 2017.
  • In the past 5 years, Supernus Pharmaceuticals' Non-Current Deffered Revenue registered a high of $1.7 million during Q1 2016, and its lowest value of $738000.0 during Q2 2013.
  • Over the past 5 years, Supernus Pharmaceuticals' median Non-Current Deffered Revenue value was $1.3 million (recorded in 2014), while the average stood at $1.3 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Non-Current Deffered Revenue surged by 35857.61% in 2013, and later crashed by 2345.1% in 2017.
  • Over the past 5 years, Supernus Pharmaceuticals' Non-Current Deffered Revenue (Quarter) stood at $1.4 million in 2013, then fell by 10.09% to $1.3 million in 2014, then rose by 9.11% to $1.4 million in 2015, then increased by 7.99% to $1.5 million in 2016, then decreased by 23.45% to $1.1 million in 2017.
  • Its Non-Current Deffered Revenue stands at $1.1 million for Q4 2017, versus $1.2 million for Q3 2017 and $1.3 million for Q2 2017.